Seminoma surgery

Jump to navigation Jump to search

Seminoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Seminoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

TNM
Stage Grouping

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Treatment - Stage I
Treatment - Stage II
Treatment - Stage III
Treatment - Recurrent

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Seminoma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Seminoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Seminoma surgery

CDC on Seminoma surgery

Seminoma surgery in the news

Blogs on Seminoma surgery

Directions to Hospitals Treating Seminoma

Risk calculators and risk factors for Seminoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Surgery is the mainstay of treatment for seminoma. The feasibility of surgery depends on the stage of seminoma at diagnosis which include: radical inguinal orchiectomy, retroperitoneal lymph node dissection, salvage surgery and surgery for metastases.

Surgery

  • Surgery is usually reserved for majority of patients.The feasibility of surgery depends on the stage of seminomsat diagnosis.[1][2][3]
  • The feasibility of surgery depends on the stage of seminoma at diagnosis.
  • Surgery is the mainstay of treatment for seminoma which include:[4][5][6][7]

Radical Inguinal Orchiectomy

  • Among patients who present with clinically advanced disease, radical orchiectomy is useful to remove the tumor prior to chemotherapy when possible.

Retroperitoneal Lymph Node Dissection

Salvage Surgery

  • Among patient who dose not response to chemotherapy after orchiectomy the surgery used to remove residual disease is called salvage surgery.[9][10]
  • Salvage surgery may include a bilateral RPLND.[11]

Surgery for Metastases

References

  1. Batool A, Karimi N, Wu XN, Chen SR, Liu YX (May 2019). "Testicular germ cell tumor: a comprehensive review". Cell. Mol. Life Sci. 76 (9): 1713–1727. doi:10.1007/s00018-019-03022-7. PMID 30671589.
  2. Boujelbene, Noureddine; Cosinschi, Adrien; Boujelbene, Nadia; Khanfir, Kaouthar; Bhagwati, Shushila; Herrmann, Eveleyn; Mirimanoff, Rene-Olivier; Ozsahin, Mahmut; Zouhair, Abderrahim (2011). "Pure seminoma: A review and update". Radiation Oncology. 6 (1). doi:10.1186/1748-717X-6-90. ISSN 1748-717X.
  3. Al-Salem, Ahmed H. (2014). "Testicular Tumors": 505–511. doi:10.1007/978-3-319-06665-3_64.
  4. Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). "Pure seminoma: a review and update". Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMC 3163197. PMID 21819630.
  5. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V (October 2013). "Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann. Oncol. 24 Suppl 6: vi125–32. doi:10.1093/annonc/mdt304. PMID 24078656.
  6. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J (December 2007). "Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors". J. Clin. Oncol. 25 (35): 5603–8. doi:10.1200/JCO.2007.13.6283. PMID 17998544.
  7. 7.0 7.1 Lavery HJ, Bahnson RR, Sharp DS, Pohar KS (October 2009). "Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors". Ther Adv Urol. 1 (4): 199–207. doi:10.1177/1756287209350315. PMC 3126061. PMID 21789067.
  8. Surgery for testicular cancer. Canadian cancer society 2016. http://www.cancer.ca/en/cancer-information/cancer-type/testicular/treatment/surgery/?region=on. Accessed on March 2, 2016
  9. Daneshmand S, Djaladat H, Nichols C (August 2011). "Management of residual mass in nonseminomatous germ cell tumors following chemotherapy". Ther Adv Urol. 3 (4): 163–71. doi:10.1177/1756287211418721. PMC 3175700. PMID 21969846.
  10. Heidenreich A, Pfister D (August 2012). "Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice". Ther Adv Urol. 4 (4): 187–205. doi:10.1177/1756287212443170. PMC 3398597. PMID 22852029.

Template:WH Template:WS